Li Zhongwen, Wu Xiaoliang, Gu Ling, Shen Qi, Luo Wen, Deng Chuangzhong, Zhou Qianghua, Chen Xinru, Li Yanjie, Lim ZuanFu, Wang Xing, Wang Jiahong, Yang Xianzi
Department of Oncology, Affiliated Hospital of Zunyi Medical University, Zunyi, China.
Department of Oncology, Guizhou Provincial People's Hospital, Guiyang, China.
Cell Death Dis. 2017 Jun 22;8(6):e2888. doi: 10.1038/cddis.2017.245.
Esophageal squamous cell carcinoma (ESCC) is one of the leading causes of cancer-related death, especially in China. In addition, the prognosis of late stage patients is extremely poor. However, the biological significance of the long non-coding RNA lnc-ATB and its potential role in ESCC remain to be documented. In this study, we investigated the role of lnc-ATB and the underlying mechanism promoting its oncogenic activity in ESCC. Expression of lnc-ATB was higher in ESCC tissues and cell lines than that in normal counterparts. Upregulated lnc-ATB served as an independent prognosis predictor of ESCC patients. Moreover, loss-of-function assays in ESCC cells showed that knockdown of lnc-ATB inhibited cell proliferation and migration both in vitro and in vivo. Mechanistic investigation indicated that lnc-ATB exerted oncogenic activities via regulating Kindlin-2, as the anti-migration role of lnc-ATB silence was attenuated by ectopic expression of Kindlin-2. Further analysis showed that lnc-ATB functions as a molecular sponge for miR-200b and Kindlin-2. Dysregulated miR-200b/Kindlin-2 signaling mediated the oncogenic activity of lnc-ATB in ESCC. Our results suggest that lnc-ATB predicts poor prognosis and may serve as a potential therapeutic target for ESCC patients.
食管鳞状细胞癌(ESCC)是癌症相关死亡的主要原因之一,在中国尤其如此。此外,晚期患者的预后极差。然而,长链非编码RNA lnc-ATB的生物学意义及其在ESCC中的潜在作用仍有待证实。在本研究中,我们调查了lnc-ATB的作用及其促进ESCC致癌活性的潜在机制。lnc-ATB在ESCC组织和细胞系中的表达高于正常对照。lnc-ATB上调是ESCC患者的独立预后预测指标。此外,ESCC细胞中的功能丧失实验表明,敲低lnc-ATB在体外和体内均抑制细胞增殖和迁移。机制研究表明,lnc-ATB通过调节Kindlin-2发挥致癌活性,因为Kindlin-2的异位表达减弱了lnc-ATB沉默的抗迁移作用。进一步分析表明,lnc-ATB作为miR-200b和Kindlin-2的分子海绵发挥作用。失调的miR-200b/Kindlin-2信号传导介导了lnc-ATB在ESCC中的致癌活性。我们的结果表明,lnc-ATB预示着预后不良,可能成为ESCC患者的潜在治疗靶点。